ivabradine has been researched along with Long QT Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Kochhäuser, S; Lange, PS; Leitz, P; Weller, J | 1 |
| Mittal, SR | 1 |
| Bellin, M; Chen, Z; Dorn, T; Dreizehnter, L; Goedel, A; Hinkel, R; Laugwitz, KL; Lipp, P; Moretti, A; Mummery, CL; Ng, JK; Pane, LS; Schneider, CM; Sinnecker, D; Tian, Q; Ward-van Oostwaard, D; Xian, W | 1 |
3 other study(ies) available for ivabradine and Long QT Syndrome
| Article | Year |
|---|---|
Ivabradine Aggravates the Proarrhythmic Risk in Experimental Models of Long QT Syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Heart Conduction System; Heart Rate; Isolated Heart Preparation; Ivabradine; Long QT Syndrome; Potassium; Rabbits; Risk Assessment; Sotalol; Tachycardia, Ventricular; Time Factors; Veratridine | 2019 |
Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine.
Topics: Acetanilides; Aged, 80 and over; Angina, Unstable; Benzazepines; Bradycardia; Diltiazem; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Electrocardiography; Female; Humans; Ivabradine; Long QT Syndrome; Piperazines; Ranolazine; Torsades de Pointes | 2014 |
Subtype-specific promoter-driven action potential imaging for precise disease modelling and drug testing in hiPSC-derived cardiomyocytes.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Case-Control Studies; Cisapride; Drug Evaluation; Humans; Induced Pluripotent Stem Cells; Ivabradine; Long QT Syndrome; Luminescent Proteins; Models, Cardiovascular; Myocytes, Cardiac; Potassium Channel Blockers; Voltage-Sensitive Dye Imaging | 2017 |